Linperlisib [1702816-75-8]
Cat# T6330-10mg
Size : 10mg
Marca : TargetMol
Linperlisib
(Synonyms: PI3Kδ-IN-2) Copy Product Info
Linperlisib (YY-20394) is a selective PI3K inhibitor that demonstrates potent antiproliferative and pro-apoptotic effects in acute myeloid leukemia cell models. In U937 cell cultures, the compound induces cell cycle arrest in a concentration-dependent manner, with 5 µM treatment blocking cells primarily in G1 phase and 10 µM shifting arrest to G2 phase. Notably, its anti-leukemic activity occurs through PI3K/Akt/mTOR-independent pathways, making it a valuable tool for investigating alternative signaling mechanisms in cancer biology. This compound is suitable for in vitro studies exploring cell cycle regulation and apoptosis induction.
Cas No. 1702816-75-8
With extensive experience in compound synthesis, we can provide rapid custom synthesis services for this product according to your research needs.
For research use only—not for human use. No sales to individuals. Use as intended only.
Select Batch
Purity:99.01%
Appearance:Solid
Color:White
COA LCMS HNMR
Product Information
Linperlisib AI Summary
Linperlisib inhibits SARS-CoV-2 3CL-Pro protease by 5.13% at a 20 µM concentration through a FRET response from a peptide substrate. Additionally, it exhibits antiviral activity against SARS-CoV-2 by inhibiting cytotoxicity in VERO-6 cells at a 10 µM concentration after 48 hours of viral exposure, although the assay results indicate an inhibition rate of -0.26%..
Note: Summary generated by AI. Data source: ChEMBL 
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | Linperlisib (YY-20394) is a selective PI3K inhibitor that demonstrates potent antiproliferative and pro-apoptotic effects in acute myeloid leukemia cell models. In U937 cell cultures, the compound induces cell cycle arrest in a concentration-dependent manner, with 5 µM treatment blocking cells primarily in G1 phase and 10 µM shifting arrest to G2 phase. Notably, its anti-leukemic activity occurs through PI3K/Akt/mTOR-independent pathways, making it a valuable tool for investigating alternative signaling mechanisms in cancer biology. This compound is suitable for in vitro studies exploring cell cycle regulation and apoptosis induction. |
| Targets & IC50 | PI3Kδ:6.4 nM |
| Synonyms | PI3Kδ-IN-2 |
| Molecular Weight | 588.694 |
| Formula | C28H37FN6O5S |
| Cas No. | 1702816-75-8 |
| Smiles | COC1=NC=C(C=C1NS(C)(=O)=O)C1=C2C=C(F)C=C(CN3CCC(CC3)C(C)(C)O)C2=NC(=N1)N1CCOCC1 |
| Relative Density. | 1.355 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 98.00 mg/mL (166.47 mM), Sonication is recommended.  | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 9.80 mg/mL (16.65 mM), Solution. 10% DMSO+90% Saline: < 9.8 mg/mL (16.65 mM), Lower concentrations may be soluble, but exact solubility limit is unknown. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density. | ||||||||||||||||||||||||||||||||||||